

- Arterial diseases, of extremities (*Cont.*):  
 popliteal artery entrapment, 1647  
 Raynaud's phenomenon. *See* Raynaud's phenomenon  
 thoracic outlet compression syndrome, 1646–1647  
 thromboangiitis obliterans, 1645–1646, 1649
- Arterial O<sub>2</sub> concentration, 1748t
- Arterial spin labeling, in MRI, 440e-8
- Arterial thoracic outlet syndrome, 122
- Arterial thrombosis, **275, 741**  
 in acute limb ischemia, 1646  
 in antiphospholipid syndrome, 2135–2136, 2135t  
 genetic considerations in, 277, 277t, 742–743, 743t  
 lupus anticoagulant in, 740  
 mesenteric, 1979–1980, 1980t  
 platelets in, 275–276, 275f, 741–742, 741f, 745–746  
 risk factors for, 405t, 745  
 vascular disease and, 275, 741  
 vs. venous thrombosis, 744–745
- Arterial volume, effective, reduction in, 250
- Arteries. *See* Blood vessels
- Arteriovenous fistula  
 acquired, 1647  
 clinical features of, 367, 1647  
 congenital, 1647  
 coronary, 1523  
 diagnosis of, 1647  
 for dialysis access, 1823  
 dural, 2586  
 pulmonary, cyanosis in, 249  
 treatment of, 1647
- Arteriovenous malformation (AVM)  
 cerebral, 2585–2586  
 hemoptysis in, 245  
 in Osler-Weber-Rendu syndrome, 732  
 pulmonary, 308e-17f, 1666  
 spinal cord, 2657, 2658f
- Arteriovenous O<sub>2</sub> difference, 1748t
- Arteritis  
 giant cell (temporal). *See* Giant cell arteritis (temporal arteritis)  
 necrotizing, 2567–2568  
 obliterative, 391e-2–3  
 Takayasu's. *See* Takayasu's arteritis
- Artery of Percheron, occlusion of, 2575
- Artery-to-artery embolic stroke, 2564–2565. *See also* Ischemic stroke
- Artesunate  
 action of, 246e-7  
 adverse effects of, 1380t  
 drug interactions of, 246e-2t  
 for malaria, 780t, 1378t, 1379, 1380t  
 pharmacology of, 246e-7, 1380t  
 in pregnancy and lactation, 246e-2t  
 resistance to, 1379
- Arthritis/arthropathy. *See also* Osteoarthritis (OA)  
 in acromegaly, 2240–2241  
 in ankylosing spondylitis, 2170  
 back pain in, 117  
 bacterial. *See* Infectious (septic) arthritis  
 in complex regional pain syndrome, 2246  
 costochondritis and, 2246  
 crystal-induced, 2233, 2233t  
 calcium apatite deposition disease, 2236–2237, 2236t, 2237f  
 calcium oxalate deposition disease, 2237, 2237f  
 calcium pyrophosphate deposition disease, 2235–2236, 2235t, 2236f  
 gout. *See* Gout  
 differential diagnosis of, 833t  
 enteropathic. *See* Enteropathic arthritis  
 in familial Mediterranean fever, 2213  
 gonococcal. *See* Gonococcal infections, disseminated  
 in hemochromatosis, 2241  
 in hemophilia, 2241–2242  
 in HIV infection, 1261  
 in hyperlipidemia, 2242–2243  
 hypertrophic. *See* Hypertrophic osteoarthropathy  
 in IBD, 1958  
 infectious. *See* Infectious (septic) arthritis  
 juvenile, 373e-7–8, 373e-8t  
 in Lyme disease, 1151  
 monoarticular, 833t  
 in myofascial pain syndrome, 93, 237, 2246  
 neoplasias and, 2246–2247  
 neuropathic, 1136, 2243–2244, 2243f, 2243t  
 new-onset, in hospitalized patient, 2219  
 ochronotic, 434e-4  
 paraneoplastic, 2247  
 polyarticular, 833t  
 postinfectious, 837. *See also* Reactive arthritis (Reiter's syndrome)  
 psoriatic. *See* Psoriatic arthritis  
 with rash, 1312t, 1313  
 in relapsing polychondritis, 2203  
 in sickle cell disease, 2242, 2242t  
 in Sjögren's syndrome, 2167, 2167t  
 in SLE, 2127, 2129t  
 in thalassemia, 2242  
 in Tietze syndrome, 2246
- Arthroconidia, 1335
- Arthrogryposis, 462e-9
- Arthropathy. *See* Musculoskeletal disorders
- Arthroplasty, 2233. *See also* Knee replacement
- Arthropod-borne viruses, **1304**. *See also specific viruses*  
 diagnosis of, 1310  
 disease syndromes of. *See also specific diseases*  
 arthritis and rash, 1312t, 1313–1314  
 encephalitis, 1312t, 1314–1317  
 fever and myalgia, 1312t, 1314–1319  
 hemorrhagic fevers. *See* Viral hemorrhagic fevers  
 pulmonary disease, 1312t  
 epidemiology of, 1310  
 geographic distribution of, 1311–1312t  
 reservoirs and vectors of, 1306–1310t  
 transmission of, 1304
- Arthropod injuries, 2744. *See also specific organisms*
- Arthroscopy, 2233
- Artificial saliva, 216
- Artificial tears, 199
- Art of medicine, 1
- ARVC. *See* Arrhythmogenic right ventricular cardiomyopathy (ARVC)
- ARX gene mutations, 2354t
- Asacol, 1959
- Asbestos, 477t, 1688–1689, 1688t
- Asbestos-related disease  
 asbestosis, 1689, 1689f  
 chest imaging in, 1689, 1689f  
 CT in, 308e-15f  
 lung cancer, 506, 1689. *See also* Lung cancer mesothelioma, 1689. *See also* Mesothelioma risk of, 1689  
 soft tissue sarcoma, 119e-1
- Ascaris lumbricoides*/ascariasis, **1413**  
 clinical features of, 1413, 1414t, 1686–1687  
 diagnosis of, 245e-3t, 245e-5t, 245e-6t, 765t, 1413, 2084  
 epidemiology of, 245e-3t, 765t, 1413  
 life cycle of parasite, 245e-3t, 1413  
 treatment of, 246e-8, 246e-11–12, 1413–1414, 1414t
- Ascites, **286**  
 in cardiovascular disease, 1443  
 chylous, 287  
 in cirrhosis, 250, 286, 2064, 2065f  
 clinical features of, 2065  
 complications of, 288, 2065–2066  
 definition of, 251, 2064  
 diagnosis of, 287–288, 287f, 2065  
 etiology of, 285, 287  
 in heart failure, 1504  
 in hepatocellular carcinoma, 545  
 with jaundice, 283  
 in liver disease, 1992  
 malignant, 288, 474  
 in ovarian cancer, 593  
 pancreatic, 288, 2087t, 2088  
 pathogenesis of, 286–287, 287f, 2064–2065, 2065f  
 peritonitis and, 288, 846, 2065–2066  
 refractory, 2065, 2065f  
 treatment of, 288, 2065, 2065f
- Ascorbic acid. *See* Vitamin C
- ASD. *See* Atrial septal defect (ASD)
- Asenapine, 2721, 2722t
- Asherman's syndrome, 335
- Ashkenazi Jewish population  
 BRCA gene testing in, 101e-6  
 dystonia in, 2620  
 factor XI deficiency in, 736  
 Gaucher's disease in, 432e-5. *See also* Gaucher's disease  
 hearing loss in, 220  
 PD in, 2609  
 Tay-Sachs disease in, 432e-1. *See also* Tay-Sachs disease
- Ash leaf spot, 344, 359
- Asialoglycoprotein receptor, 372e-24t
- Asimultanagnosia, 2575
- Askin's tumor, 119e-4
- Asparaginase, 103e-11t, 103e-14, 607t, 1798
- Aspartate aminotransferase (AST)  
 in acute viral hepatitis, 2016  
 in alcoholic liver disease, 2053, 2053t  
 in autoimmune hepatitis, 2050  
 in chronic HBV infection, 2033  
 in liver function evaluation, 1997, 1998t  
 reference values for, 2757t  
 in SLE, 2131
- Aspartylglucosaminuria, 432e-3t
- Aspergilloma, 1347, 1349t
- Aspergillus*  
 aflatoxin B<sub>1</sub> and, 544  
 antifungal susceptibility testing, 150e-8  
 ecology of, 1345  
 epidemiology of, 1345  
 laboratory identification of, 1330, 1348
- Aspergillus* infections, **1345**  
 in burn wounds, 166e-1, 166e-3  
 in cancer patient, 486t, 488, 488t, 491  
 clinical features of, 489, **1346**  
 aspergilloma, 1347  
 cerebral, 441e-9–10f, 1346–1347, 1346t  
 chronic meningitis, 908t  
 cutaneous, 25e-10f, 76e-12f, 135, 1346t, 1347  
 endocarditis, 1346t, 1347  
 keratitis, 1348  
 otitis externa, 229, 1348  
 respiratory tract. *See below*  
 diagnosis of, 489, 1346t, 1348  
 disseminated, 25e-10f, 1346  
 epidemiology of, 1345, 1346t  
 genetic considerations in, 1346  
 in HIV infection, 1255  
 pathogenesis of, 1345–1346  
 prevention of, in hospitals, 491, 492, 845  
 prognosis of, 1349  
 prophylaxis for, 1349  
 respiratory tract  
 allergic bronchopulmonary. *See* Allergic bronchopulmonary aspergillosis (ABPA)  
 allergic sinusitis, 1348  
 in asthma, 1348  
 in cancer patient, 489  
 chronic pulmonary disease, 1347, 1347f  
 chronic sinusitis, 228, 1347  
 invasive pulmonary disease, 1346, 1346t  
 invasive sinusitis, 441e-10–11f, 1346  
 tracheobronchitis, 1346  
 risk factors for, 1345–1346  
 in transplant recipient, 320e-4, 920, 925, 926  
 treatment of, 1348–1349, 1349f, 1349t
- Aspergillus terreus*, 491
- Asphyxiant/blood agents, 262e-1t, 262e-2t. *See also* Cyanide poisoning